On October 1, 2026 Tempus AI, Inc. (NASDAQ: TEM) reported that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23–27 in Madrid.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At this year’s congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid tumors, including prostate, breast, non-small cell lung cancer (NSCLC), renal cell carcinoma and gynecologic malignancies. In addition to scientific presentations, Tempus will highlight its AI-enabled technology and product offerings, including Tempus Lens, Tempus One, and its foundation models, at booths #1068 & #1069.
"Across 13 abstracts at ESMO (Free ESMO Whitepaper), researchers are using Tempus’ real-world multimodal data to identify clinically meaningful differences in cancer biology, treatment response and patient outcomes," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "By connecting molecular data with clinical histories and outcomes, these studies are generating insights that can inform biomarker development, patient stratification and clinical trial design, helping to advance precision oncology research."
Friday, October 23; 15:15 – 16:00 CET
Clinicogenomic differences between early-onset (EO-PCa) and average-onset prostate cancer (AO-PCa): A retrospective cohort study
Presentation Number: 2256P
Context-dependent prognostic impact of PTEN alterations (alt) in patients with metastatic androgen pathway modulation sensitive (mAPMS) prostate cancer
Presentation Number: 2279P
De novo vs metachronous metastatic prostate cancer (mPC): A comprehensive clinicogenomic analysis
Presentation Number: 2225P
Genomic characterization and prognostic impact of the TP53-Y220C mutation across solid tumors in real-world data
Presentation Number: 4461P
Genomic landscape in early-onset breast cancer: A comprehensive analysis from the Tempus database
Presentation Number: 4307P
Real-world implementation of large-panel ctDNA NGS testing in metastatic NSCLC and colorectal cancer: interim results of the multicenter LOLA Project
Presentation Number: 3283P
Sunday, October 25; 12:00 – 12:45 CET
Novel immune archetypes stratify overall survival and refine the prognostic landscape in head and neck squamous cell carcinoma
Presentation Number: 359P
A comprehensive AI-enabled pre-screening panel for non-small cell lung carcinoma (NSCLC) using computational pathology applied to H&E whole slide images (WSI)
Presentation Number: 320P
Monday, October 26; 12:00 – 12:45 CET
Landscape of somatic alterations and real-world outcomes of ovarian cancer associated with ATM mutations
Presentation Number: 1323P
Real-world impact of vascular endothelial growth factor (VEGF) on (chemo)immunotherapy (IO) response in non-small cell lung cancer (NSCLC)
Presentation Number: 2704P
Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with advanced gynecologic malignancies
Presentation Number: 1319P
E-Posters
Higher GCN2 expression is associated with favorable clinical and genomic features in advanced prostate cancer
Presentation Number: 2306eP
GCN2 RNA expression identifies a distinct immunologically cold and genomically favorable phenotype in advanced renal cell carcinoma
Presentation Number: 3644eP
Learn more about Tempus at ESMO (Free ESMO Whitepaper) Congress 2026 here.
(Press release, Tempus, OCT 1, 2026, View Source [SID1234671230])